{"schema_version":"secwatch.filing_event.v1","accession":"0001158172-25-000010","form_type":"8-K","ticker":"SCOR","cik":"0001158172","company_name":"COMSCORE, INC.","filed_at":"2025-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.049734+00:00","generated_at":"2026-05-27T04:34:11.341516+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Chief Innovation Officer David Algranati to leave comScore on Feb 1, 2025","bullets":["Dr. Algranati's employment ends February 1, 2025 under a Separation Agreement dated January 27.","Severance includes 12 months of payments and benefits per the prior Severance Agreement (May 2019).","Eligible for 2024 annual bonus under short-term incentive program, payable no later than March 15, 2025.","Agreed to release of claims and reaffirmed non-disclosure, non-competition, and non-solicitation covenants."],"urls":{"canonical":"https://secwatch.observer/filing/0001158172-25-000010","json":"https://secwatch.observer/filing/0001158172-25-000010.json","markdown":"https://secwatch.observer/filing/0001158172-25-000010.md","text":"https://secwatch.observer/filing/0001158172-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1158172/000115817225000010/0001158172-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1158172/000115817225000010/scor-20250127.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:34:11.341516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3debbf7b2d","claim":"David Algranati departed as Chief Innovation Officer at COMSCORE, INC..","evidence_excerpt":"On January 27, 2025, the Company and Dr. Algranati entered into a Separation and General Release Agreement (the \"Separation Agreement\"), pursuant to which Dr. Algranati's employment with the Company will end on February 1, 2025 (the \"Separation Date\").","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1158172/000115817225000010/0001158172-25-000010-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will leave"},{"label":"Role","value":"Chief Innovation Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}